BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 37624556)

  • 1. Use of Real-World Evidence for Drug Regulatory Decisions in China: Current Status and Future Directions.
    Li P; Wang S; Chen Y
    Ther Innov Regul Sci; 2023 Nov; 57(6):1167-1179. PubMed ID: 37624556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Real-World Evidence in Regulatory Decisions for Traditional Chinese Medicine: Current Status and Future Directions.
    Li P; Wang S; Chen Y
    Ther Innov Regul Sci; 2024 Jan; 58(1):34-41. PubMed ID: 37996768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval-An Industry Perspective.
    Zhu R; Vora B; Menon S; Younis I; Dwivedi G; Meng Z; Datta-Mannan A; Manchandani P; Nayak S; Tammara BK; Garhyan P; Iqbal S; Dagenais S; Chanu P; Mukherjee A; Ghobadi C;
    Clin Pharmacol Ther; 2023 Oct; 114(4):751-767. PubMed ID: 37393555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of real-world evidence to support regulatory decisions on medical devices in China and a unique opportunity to gain accelerated approval in "Boao Lecheng Pilot Zone".
    Li J; Liu L; Cao H; Yang M; Sun X
    Cost Eff Resour Alloc; 2023 Jan; 21(1):7. PubMed ID: 36653783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
    Wu J; Wang C; Toh S; Pisa FE; Bauer L
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving Acceptance and Use of RWE for Regulatory Decision Making on the Benefit/Risk Assessment of a Drug in Japan.
    Nishioka K; Makimura T; Ishiguro A; Nonaka T; Yamaguchi M; Uyama Y
    Clin Pharmacol Ther; 2022 Jan; 111(1):35-43. PubMed ID: 34528701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The application of real-world evidence in drug regulatory decision-making].
    Wicherski J; Haenisch B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2024 Feb; 67(2):149-154. PubMed ID: 38214723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of Real-World Evidence in European Medicines Agency's Regulatory Decision Making.
    Bakker E; Plueschke K; Jonker CJ; Kurz X; Starokozhko V; Mol PGM
    Clin Pharmacol Ther; 2023 Jan; 113(1):135-151. PubMed ID: 36254408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward.
    Lou J; Kc S; Toh KY; Dabak S; Adler A; Ahn J; Bayani DBS; Chan K; Choiphel D; Chua B; Genuino AJ; Guerrero AM; Kearney B; Lin LW; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Shafie AA; Sui B; Suwantika A; Teerawattananon Y; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Wee HL
    Int J Technol Assess Health Care; 2020 Oct; 36(5):474-480. PubMed ID: 32928330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating Real-World Evidence in the Regulatory Decision-Making Process: A Systematic Analysis of Experiences in the US, EU, and China Using a Logic Model.
    Li M; Chen S; Lai Y; Liang Z; Wang J; Shi J; Lin H; Yao D; Hu H; Ung COL
    Front Med (Lausanne); 2021; 8():669509. PubMed ID: 34136505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two assessments of real-world data and real-world evidence for regulatory decision-making.
    Yuan L; Rahman M; Concato J
    Clin Transl Sci; 2024 Jan; 17(1):e13702. PubMed ID: 38093484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan.
    Hiramatsu K; Barrett A; Miyata Y;
    Drugs Real World Outcomes; 2021 Dec; 8(4):459-480. PubMed ID: 34148219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia.
    Webster J; Smith BD
    Clin Ther; 2019 Feb; 41(2):336-349. PubMed ID: 30709609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What, Where, and How to Collect Real-World Data and Generate Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia: A reflection Into the Past and A Way Forward.
    Kc S; Lin LW; Bayani DBS; Zemlyanska Y; Adler A; Ahn J; Chan K; Choiphel D; Genuino-Marfori AJ; Kearney B; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Akmal Shafie A; Sui B; Suwantika A; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Teerawattananon Y; Wee HL
    Int J Health Policy Manag; 2023; 12():6858. PubMed ID: 37579427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Current Landscape and Emerging Applications for Real-World Data in Diagnostics and Clinical Decision Support and its Impact on Regulatory Decision Making.
    Baumfeld Andre E; Carrington N; Siami FS; Hiatt JC; McWilliams C; Hiller C; Surinach A; Zamorano A; Pashos CL; Schulz WL
    Clin Pharmacol Ther; 2022 Dec; 112(6):1172-1182. PubMed ID: 35213741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world evidence: perspectives on challenges, value, and alignment of regulatory and national health technology assessment data collection requirements.
    Sievers H; Joos A; Hiligsmann M
    Int J Technol Assess Health Care; 2021 Feb; 37():e40. PubMed ID: 33622423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trial designs using real-world data: The changing landscape of the regulatory approval process.
    Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018-2019.
    Eskola SM; Leufkens HGM; Bate A; De Bruin ML; Gardarsdottir H
    Clin Pharmacol Ther; 2022 Jan; 111(1):310-320. PubMed ID: 34689334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Real-World Evidence in Neuroscience-Related New Drug and Biologics License Applications for Novel Therapeutics.
    Bloomfield-Clagett B; Rahman M; Smith K; Concato J
    Clin Pharmacol Ther; 2023 Nov; 114(5):1002-1005. PubMed ID: 37548904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Payer perceptions of the use of real-world evidence in oncology-based decision making.
    Brixner D; Biskupiak J; Oderda G; Burgoyne D; Malone DC; Arondekar B; Niyazov A
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1096-1105. PubMed ID: 34337998
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.